On Monday, Advaxis, Inc. (NASDAQ:ADXS)’s shares surged 4.36% to $20.59, hitting its highest level, after a clinical stage biotechnology company, declared that its stock has been added to the Loncar Cancer Immunotherapy Index (LCINDX). Based on current allocations and current share prices, Advaxis is the most heavily weighted stock in LCINDX.
The Loncar Cancer Immunotherapy Index (LCINDX), produced by Loncar Investments, LLC, is the first professional index to track the transformational immunotherapy field within the biotechnology space. LCINDX seeks to track the performance of a basket of companies that develops therapies to treat cancer by harnessing the body’s own immune system. The index will provide a metric to follow its progress as researchers advance new technologies for the benefit of patients who fight cancer disease. LCINDX is an index containing both large pharmaceutical and growth-oriented biotechnology companies that are leading in immunotherapy.
LCINDX is a professional index of 25 top immunotherapy companies rebalanced and reconstituted on a semi-annual basis. Of the 25 holdings, six are large pharma companies and 19 are growth biotech companies. Price and return data are independently calculated on a daily basis by Indxx, LLC.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor.
Gigamon Inc. (NYSE:GIMO)’s shares gained 4.24% to $23.85, during the last trading session on Monday, hitting its highest level, as Gigamon declared that it will release its financial results for the first quarter ended March 28, 2015 after the market closes on Thursday, April 23, 2015. The company will host a conference call and live webcast for analysts and investors at 5:00 p.m. Eastern time on that day. The news release with the financial results will be accessible from the company’s website preceding to the conference call.
Gigamon Inc. designs, develops, and sells products and services that provide customers with visibility and control of network traffic for enterprises and services providers in the United States, rest of Americas, Europe, the Middle East, Africa, and the Asia Pacific.
At the end of Monday’s trade, BancorpSouth, Inc. (NYSE:BXS)’s shares gained 4.34% to $24.29, after a financial holding company opened a loan and deposit production office at 14841 North Dallas Parkway, Suite 135, in Dallas, Texas, providing a broad range of financial services to the Dallas metropolitan area.
BancorpSouth’s Dallas team comprises of a group of financial services veterans, counting Thomas Wilds, Market President, Joseph Massey, Senior Vice President and Commercial Lender, and Kathy Loredo, Senior Loan Administrative Assistant.
The BancorpSouth team is focusing on providing clients a broad range of commercial and consumer banking services, counting commercial real estate, construction, residential and consumer lending.
BancorpSouth Bank presently operates 24 banking offices in Texas, counting loan and deposit production offices in Austin, Houston, Sugar Land and Dallas.
BancorpSouth, Inc. operates as a financial holding company for BancorpSouth Bank that provides commercial banking and financial services to individuals and small-to-medium size businesses. It offers various deposit products, counting interest bearing and noninterest bearing demand deposits, and saving and time deposits.
Finally, Kite Pharma, Inc. (NASDAQ:KITE), ended its Monday’s trading session with 4.22% gain, and closed at $60.80, as a clinical-stage biopharmaceutical company, declared that Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer, will present a company overview at the 2015 Jefferies Immuno-Oncology Summit in Boston. The presentation will take place on Wednesday, April 15, 2015, at 8:10 a.m. EDT.
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
